Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Nagata, Masayoshi ^a   Muto, Satoru ^b   Horie, Shigeo ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICRORNA; MICRORNA 125B; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 17 5P; MICRORNA 183; MICRORNA 205; MICRORNA 20A; MICRORNA 214; MICRORNA 29; MICRORNA 29C; MICRORNA 497; MOLECULAR MARKER; PROTEIN; PROTEIN P53; RB1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; TUMOR SUPPRESSOR PROTEIN;

BLADDER BIOPSY; BLADDER CARCINOGENESIS; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DISEASE SPECIFIC SURVIVAL; DOWN REGULATION; EXOSOME; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUID BIOPSY; MUSCLE INVASIVE BLADDER CANCER; NEXT GENERATION SEQUENCING; NON MUSCLE INVASIVE BLADDER CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR BIOPSY; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR EMBOLISM; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84957991723     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/8205836     Document Type: Review

References (57)

1. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008," International Journal of Cancer, vol. 127, no. 12, pp. 2893-2917, 2010.
2. T. R. L. Griffiths, "Current perspectives in bladder cancer management," International Journal of Clinical Practice, vol. 67, no. 5, pp. 435-448, 2013.
3. G. R. Prout Jr., B. A. Barton, P.P. Griffin et al., "Treated history of noninvasive grade 1 transitional cell carcinoma," The Journal of Urology, vol. 148, no. 5I, pp. 1413-1419, 1992.
4. H. W. Herr, "Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome," Journal of Urology, vol. 163, no. 1, pp. 60-62, 2000.
5. R. J. Sylvester, A. P. van der Meijden, W. Oosterlinck et al., "Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials," European Urology, vol. 49, no. 3, pp. 466-467, 2006.
6. M. S. Soloway, "Bladder cancer: lack of progress in bladder cancer-what are the obstacles?" Nature Reviews Urology, vol. 10, no.1, pp. 5-6, 2013.
7. K. Türkölmez, H. Tokgöz, B. Reşorlu, K. Köse, and Y. Bedük, "Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors," Urology, vol. 70, no.3, pp. 477-481, 2007.
8. N. Sapre, P. Herle, P. D. Anderson, N. M. Corcoran, and C. M. Hovens, "Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder," Pathology, vol. 46, no. 4, pp. 274-282, 2014.
9. D. P. Slaughter, H. W. Southwick, and W. Smejkal, "'Field cancerization' in oral stratified squamous epithelium. Clinical implications of multicentric origin," Cancer, vol. 6, no. 5, pp. 963-968, 1953.
10. S. Muto, S. Horie, S. Takahashi, K. Tomita, and T. Kitamura, "Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer," Cancer Research, vol.60, no. 15, pp. 4021-4025, 2000.
11. D. Sidransky, P. Frost, A. Von Eschenbach, R. Oyasu, A. C. Preisinger, and B. Vogelstein, "Clonal origin of bladder cancer," The New England Journal of Medicine, vol. 326, no. 11, pp. 737- 740, 1992.
12. T. Habuchi, R. Takahashi, H. Yamada, Y. Kakehi, T. Sugiyama, and O. Yoshida, "Metachronous multifocal development of urothelial cancers by intraluminal seeding," The Lancet, vol. 342, no.8879, pp. 1087-1088, 1993.
13. T. Takahashi, T. Habuchi, Y. Kakehi et al., "Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract," Cancer Research, vol. 58, no. 24, pp. 5835-5841, 1998.
14. C. Cordon-Cardo and V. E. Reuter, "Alterations of tumor suppressor genes in bladder cancer," Seminars in Diagnostic Pathology, vol. 14, no.2, pp. 123-132, 1997.
15. E. R. Fearon and B. Vogelstein, "A genetic model for colorectal tumorigenesis," Cell, vol. 61, no. 5, pp. 759-767, 1990.
16. M. A. Knowles and C. D. Hurst, "Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity," Nature Reviews Cancer, vol.15, no.1, pp. 25-41, 2014.
17. A. P. Feinberg, B. Vogelstein, M. J. Droller, S. B. Baylin, and B. D. Nelkin, "Mutation affecting the 12th amino acid of the c-Haras oncogene product occurs infrequently in human cancer," Science, vol. 220, no. 4602, pp. 1175-1177, 1983.
18. B. Czerniak, G. L. Cohen, P. Etkind et al., "Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas," Human Pathology, vol. 23, no. 11, pp. 1199-1204, 1992.
19. A. H. Jebar, C. D. Hurst, D. C. Tomlinson, C. Johnston, C. F. Taylor, and M. A. Knowles, "FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma," Oncogene, vol. 24, no. 33, pp. 5218-5225, 2005.
20. S. Ouerhani and A. B. A. Elgaaied, "The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer," Cancer Biomarkers, vol. 10, no. 6, pp. 259-266, 2011.
21. J. P. Sfakianos, E. K. Cha, G. Iyer et al., "Genomic characterization of upper tract urothelial carcinoma," European Urology, vol. 68, no. 6, pp. 970-977, 2015.
22. L. C. Kompier, I. Lurkin, M. N. M. van der Aa, B. W. G. van Rhijn, T. H. van der Kwast, and E. C. Zwarthoff,"FGFR3, HRAS, KRAS, NRAS AND PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy," PLoS ONE, vol. 5, no. 11, Article ID e13821, 2010.
23. C. Billerey, D. Chopin, M.-H. Aubriot-Lorton et al., "Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors," The American Journal of Pathology, vol. 158, no. 6, pp. 1955-1959, 2001.
24. B. W. G. van Rhijn, I. Lurkin, F. Radvanyi, W. J. Kirkels, T. H. Van der Kwast, and E. C. Zwarthoff, "The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate," Cancer Research, vol. 61, no. 4, pp. 1265-1268, 2001.
25. J. Bourdin, X. Sastre-Garau, D. Chopin, J. P. Thiery, and F. Radvanyi, "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas," Nature Genetics, vol. 23, no. 1, pp. 18-20, 1999.
26. B. W. G. van Rhijn, T. H. van der Kwast, L. Liu et al., "The FGFR3 mutation is related to favorable pT1 bladder cancer," The Journal of Urology, vol. 187, no. 1, pp. 310-314, 2012.
27. D. Lindgren, F. Liedberg, A. Andersson et al., "Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q," Oncogene, vol. 25, no. 18, pp. 2685-2696, 2006.
28. D. Esrig, D. Elmajian, S. Groshen et al., "Accumulation of nuclear p53 and tumor progression in bladder cancer," The New England Journal of Medicine, vol. 331, no. 19, pp. 1259-1264, 1994.
29. N. Malats, A. Bustos, C. M. Nascimento et al., "P53 as a prognostic marker for bladder cancer: a meta-analysis and review," The Lancet Oncology, vol. 6, no. 9, pp. 678-686, 2005.
30. S. F. Shariat, C. Bolenz, P. I. Karakiewicz et al., "p53 expression in patients with advanced urothelial cancer of the urinary bladder," BJU International, vol. 105, no. 4, pp. 489-495, 2010.
31. J. A. Karam, Y. Lotan, P. I. Karakiewicz et al., "Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy," The Lancet Oncology, vol. 8, no. 2, pp. 128-136, 2007.
32. S. F. Shariat, H. Tokunaga, J. Zhou et al., "p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer," Journal of Clinical Oncology, vol. 22, no. 6, pp. 1014-1024, 2004.
33. D. Lindgren, G. Sjödahl, M. Lauss et al., "Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma," PLoS ONE, vol. 7, no. 6, Article ID e38863, 2012.
34. G. Sjödahl, M. Lauss, S. Gudjonsson et al., "A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in tsc2 and pik3r1," PLoS ONE, vol. 6, no. 4, Article ID e18583, 2011.
35. H. Adachi, M. Igawa, H. Shiina, S. Urakami, K. Shigeno, and O. Hino, "Human bladder tumors with 2-hit mutations of the tumor suppressor gene TSC1 and decreased expression of p27," Journal of Urology, vol. 170, no. 2, pp. 601-604, 2003.
36. S. Eissa, H. S. Ali, A. H. Al Tonsi, A. Zaglol, and O. El Ahmady, "HER2/neu expression in bladder cancer: relationship to cell cycle kinetics," Clinical Biochemistry, vol. 38, no. 2, pp. 142-148, 2005.
37. C. Bolenz, S. F. Shariat, P. I. Karakiewicz et al., "Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder," BJU International, vol. 106, no. 8, pp. 1216-1222, 2010.
38. F. M. Platt, C. D. Hurst, C. F. Taylor, W. M. Gregory, P. Harnden, and M. A. Knowles, "Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer," Clinical Cancer Research, vol. 15, no. 19, pp. 6008-6017, 2009.
39. H. Yoshino, N. Seki, T. Itesako, T. Chiyomaru, M. Nakagawa, and H. Enokida, "Aberrant expression of microRNAs in bladder cancer," Nature Reviews Urology, vol. 10, no. 7, pp. 396-404, 2013.
40. N. Ratert, H.-A. Meyer, M. Jung et al., "miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome," Journal of Molecular Diagnostics, vol. 15, no. 5, pp. 695-705, 2013.
41. E. Rosenberg, J. Baniel, Y. Spector et al., "Predicting progression of bladder urothelial carcinoma using microRNA expression," BJU International, vol. 112, no. 7, pp. 1027-1034, 2013.
42. B. Hong and Y. Zu, "Detecting circulating tumor cells: current challenges and new trends," Theranostics, vol. 3, no. 6, pp. 377-394, 2013.
43. A. R. Thierry, F. Mouliere, S. El Messaoudi et al., "Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA," Nature Medicine, vol. 20, no. 4, pp. 430-435, 2014.
44. E. S. Antonarakis, C. Lu, H. Wangetal., "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer," The New England Journal of Medicine, vol. 371, no. 11, pp. 1028-1038, 2014.
45. A. Alva, T. Friedlander, M. Clark et al., "Circulating tumor cells as potential biomarkers in bladder cancer," The Journal of Urology, vol. 194, no. 3, pp. 790-798, 2015.
46. F. Qi, Y. Liu, R. Zhao et al., "Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance," Tumor Biology, vol. 35, no. 7, pp. 7217-7223, 2014.
47. P. Gazzaniga, E. De Berardinis, C. Raimondi et al., "Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer," International Journal of Cancer, vol. 135, no. 8, pp. 1978-1982, 2014.
48. T. W. Flaig, S. Wilson, A. van Bokhoven et al., "Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma," Urology, vol. 78, no. 4, pp. 863-867, 2011.
49. M. Rink, F. K. Chun, R. Dahlem et al., "Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study," European Urology, vol. 61, no. 4, pp. 810-817, 2012.
50. G. van Niel, I. Porto-Carreiro, S. Simoes, and G. Raposo, "Exosomes: a common pathway for a specialized function," Journal of Biochemistry, vol. 140, no. 1, pp. 13-21, 2006.
51. C. A. Franzen, R. H. Blackwell, V. Todorovic et al., "Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes," Oncogenesis, vol. 4, article e163, 2015.
52. X. Huang, M. Liang, R. Dittmar, and L. Wang, "Extracellular microRNAs in urologic malignancies: chances and challenges," International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14785-14799, 2013.
53. X. Huang, T. Yuan, M. Liang et al., "Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer," European Urology, vol. 67, pp. 33-41, 2014.
54. B. S. Haflidadóttir and Y. Ceder, "Exosomal microRNAs as potential biomarkers in castration-resistant prostate cancer," European Urology, vol. 67, no. 1, pp. 42-43, 2015.
55. M. Du, D. Shi, L. Yuan et al., "Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer," Scientific Reports, vol. 5, article 10437, 2015.
56. J. Wang, X. Zhang, L. Wang et al., "Downregulation of urinary cell-free microRNA-214 as a diagnostic and prognostic biomarker in bladder cancer,"Journal of Surgical Oncology, vol. 111, no. 8, pp. 992-999, 2015.
57. X. Zhang, Y. Zhang, X. Liu et al., "Direct quantitative detection for cell-freemiR-155in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer," Oncotarget, 2015.